Providers

EazeTab™ is prescription-only and available exclusively through EazeTab™. Outside prescriptions are not accepted.

Available Formulations

Semaglutide

Doses

Personalized dose, taken every 5 days as prescribed
Mechanism

A GLP-1 receptor agonist that mimics a natural hormone to increase glucose-dependent insulin, lower glucagon, slow gastric emptying, and reduce appetite.

Tirzepatide

Doses

Personalized dose, taken every 5 days as prescribed
Mechanism

A dual GIP/GLP-1 receptor agonist that works on two hormone pathways to increase glucose-dependent insulin, lower glucagon, slow gastric emptying, and curb appetite.

Rx only. This is a compounded prescription prepared in office by or under the supervision of our licensed clinician for an individual patient pursuant to a valid prescription and in accordance with applicable state law. Not for resale.

Regulatory & Clinical References

Tirzepatide (Mounjaro/Zepbound) – FDA DailyMed

Semaglutide (Wegovy) – FDA DailyMed

FDA Human Drug Compounding Guidance

NEJM Tirzepatide Study

American Diabetes Association – GLP-1 Info

NEJM Semaglutide Study

Important Notice

EazeTab™ is not a telehealth company. All prescriptions are issued exclusively by our in-house practice. Outside prescriptions are not accepted.

Route

Mechanism

Neuron illustration with vibrant colors on a dark background

Mechanism & Neuroendocrine Impact

GLP-1 receptor agonists (GLP-1 RAs) act on central and peripheral targets involved in energy balance. Centrally, GLP-1Rs in the hypothalamus and brainstem (e.g., area postrema/nucleus tractus solitarius) reduce hunger and enhance satiety signaling; they also interact with mesolimbic reward circuitry (dopamine pathways), which can attenuate cue-driven food seeking and cravings. Peripherally, slowed gastric emptying and pancreatic effects (glucose-dependent insulin secretion, suppression of glucagon) contribute to glycemic control and reduced caloric intake.

Route Considerations (EazeTab™ Buccal ODT)
Buccal administration provides systemic exposure without GI transit or first-pass hepatic metabolism. In practice, this route can support earlier systemic availability compared with swallowed oral dosing and may help patients perceive earlier satiety signals, subject to individual variability and prescriber-directed titration. Compared with subcutaneous injection, buccal delivery avoids needle use and injection-site considerations and does not rely on depot absorption from subcutaneous tissue; systemic exposure results from transmucosal uptake. Dosing is prescribed on an every-5-day interval.

Doctor and patient discussing EazeTab at a desk with cityscape view

Why EazeTab™ for GLP-1 Therapy

Needle-Free Administration
Buccal ODT placed in the cheek; no injections or sharps disposal.
Direct Buccal Absorption
Absorbed through the cheek lining into nearby blood vessels, bypassing the GI tract and first-pass liver processing.
Personalized Dosing
Prescriber-directed strength and an every-5-day dosing cadence.
Simple To Take
No mixing or pens; no water or swallowing required.
Discreet and portable
Small form factor, no refrigeration needed, and suitable for on-the-go use.

Clinical & Usage Highlights

GLP-1 Mechanism of Action

Supports appetite regulation, glucose control, and metabolic balance through GLP-1 receptor activation.

Type 2 Diabetes & Metabolic Health

Used under physician supervision to help improve glycemic control and support metabolic care in adults.

Rapid Onset & Direct Absorption

Disintegrates in under 3 seconds; absorbed through the cheek lining into systemic circulation—bypassing the stomach and first-pass liver processing.

Personalized Interval Dosing

Prescriber-directed dosage with an every-5-day cadence, optimized to patient tolerance and clinical response.

Adolescent & Young Adult Access

Clinician-guided option for teens and young adults—early support for healthy metabolic management. Addresses your adolescent’s needs with medical oversight and personalized care.

Group of people playing basketball on an outdoor court with trees in the background

Ideal Patient Profiles

Adults or adolescents with obesity or type 2 diabetes who are candidates for GLP-1 therapy.
Patients with GI intolerance to swallowed dosage forms.
Patients unable or unwilling to use injections, or those who prefer a needle-free option.
Individuals with swallowing difficulty or who need/want discreet, portable dosing for work, school, or travel.
Adolescents, young adults, and adults pursuing clinician-supervised GLP-1 care in DC, Maryland, or Virginia (every-5-day dosing set by the prescriber).

Evaluate Patient

Confirm medical eligibility for GLP-1 therapy and suitability for buccal ODT.
Select Formulation

Choose semaglutide or tirzepatide; set starting dose and every-5-day cadence.
Submit Prescription

Issued exclusively through EazeTab™
Patient Fulfillment

Patient receives EazeTab™ with clear administration and storage instructions (no refrigeration needed).
Follow-Up

Monitor response and tolerability; adjust dose/titration per prescriber direction.

Get Started

Provider Inquires: support@eazetab.com
Toll-free (24/7 reception line): 1-855-EAZETAB
Local (DMV direct, no automated receptionist):
(240) 744-4687
Not for emergencies. Call 911 for urgent issues.

Partnering With You to Deliver Innovative GLP-1 Therapy

Clinical Overview

Regulatory & Clinical References

Administration